Last Update 18:58
Monday, 18 November 2019

FDA says finds 'unacceptable level' of carcinogen in Zantac and its generics

The U.S. Food and Drug Administration said on Wednesday it found “unacceptable levels” of a cancer-causing impurity in the popular heartburn drug Zantac and its generic versions known chemically as ranitidine

Reuters , Thursday 3 Oct 2019
Views: 1793
Views: 1793

U.S. and European health regulators said last month they were reviewing the safety of ranitidine, after online pharmacy Valisure flagged the impurities to regulators. Canada’s health authorities have asked makers of the drug to halt distribution as it gathers more information.

The FDA, which checked the over-the-counter drugs using a low-heat method of testing, said it found much lower levels of the impurity - N-nitrosodimethylamine (NDMA) - than was discovered with a higher temperature test employed by Valisure.

NDMA had previously been found in some blood pressure medicines from a class of drugs known as angiotensin II receptor blockers, or ARBs. The potentially cancer-causing impurities are believed to have been introduced by recent changes in the manufacturing process for the drugs.

Recalls of some ARBs since last year have led to shortages of the medicines, including valsartan, the generic of Novartis’ Diovan. The FDA has since expanded its investigation of the impurities beyond that class of drugs.

The FDA said Valisure’s higher temperature testing method generated very high levels of NDMA from the ranitidine drugs. But the agency said that method, which Valisure had used for testing ARBs, was not suitable for ranitidine.

Valisure said on Wednesday that it also suspects the high temperature method resulted in findings of higher NDMA levels. It said that it did not find NDMA in a body-temperature test of ranitidine it conducted.

Still, an analysis Valisure conducted in conditions similar to the human stomach generated over 300,000 nanograms of NDMA, significantly above acceptable levels set by the FDA, it said.

David Light, Valisure’s chief executive, said this shows that even if the pills are not contaminated, the drug is likely to form the impurity in patients’ stomachs after it is ingested.

Walmart Inc on Wednesday joined pharmacy chains CVS Health Corp, Walgreens Boots Alliance Inc and Rite Aid Corp in suspending sale of the medicines.

Last month, Novartis halted global distribution of its ranitidine drugs.

The FDA on Wednesday asked ranitidine makers to conduct their own testing to assess levels of the impurity and to send samples of their products for testing by the agency.

It will assess oral ranitidine medicines and has begun testing samples of other heartburn treatments such as proton-pump inhibitors as part of the investigation.

Short link:


Ahram Online welcomes readers' comments on all issues covered by the site, along with any criticisms and/or corrections. Readers are asked to limit their feedback to a maximum of 1000 characters (roughly 200 words). All comments/criticisms will, however, be subject to the following code
  • We will not publish comments which contain rude or abusive language, libelous statements, slander and personal attacks against any person/s.
  • We will not publish comments which contain racist remarks or any kind of racial or religious incitement against any group of people, in Egypt or outside it.
  • We welcome criticism of our reports and articles but we will not publish personal attacks, slander or fabrications directed against our reporters and contributing writers.
  • We reserve the right to correct, when at all possible, obvious errors in spelling and grammar. However, due to time and staffing constraints such corrections will not be made across the board or on a regular basis.

© 2010 Ahram Online.